Serum phosphate optimal timing and range associated with patients survival in haemodialysis: The COSMOS study

Fernández-Martín J.L.
Dusso A.
Martínez-Camblor P.
Dionisi M.P.
Floege J.
Ketteler M.
London G.
Locatelli F.
Górriz J.L.
Rutkowski B.
Bos W.-J.
Tielemans C.
Martin P.-Y.
Wüthrich R.P.
Pavlovic D.
Benedik M.
Rodríguez-Puyol D.
Carrero J.J.
Zoccali C.
Cannata-Andía J.B.
Covic A.
Ferreira A.
Goldsmith D.
Kramar R.
Background. Serum phosphate is a key parameter in the management of chronic kidney disease-mineral and bone disorder (CKD-MBD). The timing of phosphate measurement is not standardized in the current guidelines. Since the optimal range of these biomarkers may vary depending on the duration of the interdialytic interval, in this analysis of the Current management of secondary hyperparathyroidism: a multicentre observational study (COSMOS), we assessed the influence of a 2- (midweek) or 3-day (post-weekend) dialysis interval for blood withdrawal on serum levels of CKD-MBD biomarkers and their association with mortality risk. Methods. The COSMOS cohort (6797 patients, CKD Stage 5D) was divided into two groups depending upon midweek or post-weekend blood collection. Univariate and multivariate Cox's models adjusted hazard ratios (HRs) by demographics and comorbidities, treatments and biochemical parameters from a patient/centre database collected at baseline and every 6 months for 3 years. Results. There were no differences in serum calcium or parathyroid hormone levels between midweek and post-weekend patients. However, in post-weekend patients, the mean serum phosphate levels were higher compared with midweek patients (5.5 ± 1.4 versus 5.2 ± 1.4 mg/dL, P < 0.001). Also, the range of
serum phosphate with the lowest mortality risk [HR ? 1.1; midweek: 3.5-4.9 mg/dL (95% confidence interval, CI: 2.9-5.2 mg/dL); post-weekend: 3.8-5.7 mg/dL (95% CI: 3.0-6.4 mg/dL)] showed significant differences in the upper limit (P = 0.021). Conclusion. Midweek and post-weekend serum phosphate levels and their target ranges associated with the lowest mortality risk differ. Thus, clinical guidelines should consider the timing of blood withdrawal when recommending optimal target ranges for serum phosphate and therapeutic strategies for phosphate control. © 2018 The Author(s).

calcaemia
chronic haemodialysis
epidemiology
hyperparathyroidism
phosphataemia
albumin
biological marker
calcium
hemoglobin
parathyroid hormone
phosphate
biological marker
calcium
parathyroid hormone
phosphate
adult
albumin blood level
all cause mortality
Article
blood sampling
body mass
calcium blood level
chronic kidney disease-mineral and bone disorder
clinical assessment
cohort analysis
comorbidity
female
hemodialysis
hemoglobin blood level
human
major clinical study
male
middle aged
mortality risk
multicenter study
observational study
parathyroid hormone blood level
phosphate blood level
priority journal
prospective study
blood
chronic kidney disease-mineral and bone disorder
clinical trial
hemodialysis
mortality
prognosis
randomization
secondary hyperparathyroidism
survival rate
Biomarkers
Calcium
Chronic Kidney Disease-Mineral and Bone Disorder
Female
Humans
Hyperparathyroidism, Secondary
Male
Middle Aged
Parathyroid Hormone
Phosphates
Prognosis
Prospective Studies
Random Allocation
Renal Dialysis
Survival Rate